Orchard Therapeutics Announces the Build-out of New Gene Therapy Manufacturing Facility in California
New facility expected to create more than 100 new jobs, supporting extensive gene therapy pipeline
Enhances Orchard’s capacity to develop and deliver lentiviral vector and gene-corrected hematopoetic stem cells for wide range of diseases on a global scale
Once operational, the new site will provide significant additional CGMP manufacturing capacity for both lentiviral vector and cryopreserved cell therapy products, enhancing Orchard’s ability to manufacture and deliver gene-corrected hematopoetic stem cells for a wide range of diseases on a global basis. In addition to this expanded capacity, Orchard also plans to continue its close collaborations with the Company’s contract manufacturing partners.
“The expansion of our
The build-out of Orchard’s new manufacturing facility is expected to begin in 2019, and the Company expects to hire more than 100 full-time employees over the next few years to support in-house manufacturing efforts.
Orchard’s portfolio of autologous ex vivo gene therapies includes Strimvelis, the first autologous ex vivo gene therapy approved by the
Orchard currently has offices in the
This press release contains certain forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “anticipates,” and “future” or similar expressions that are intended to identify forward-looking statements. Forward-looking statements include express or implied statements relating to, among other things, Orchard’s expectations regarding the build out of its manufacturing facility in
LifeSci Public Relations
Source: Orchard Therapeutics